Vigil Neuroscience Stock Z Score
| VIGL Stock | USD 3.57 0.24 6.30% |
Vigil |
Vigil Neuroscience Company Z Score Analysis
Vigil Neuroscience's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
As per the company's disclosures, Vigil Neuroscience has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Vigil Neuroscience ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vigil Neuroscience's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vigil Neuroscience's managers, analysts, and investors.Environmental | Governance | Social |
Vigil Neuroscience Institutional Holders
Institutional Holdings refers to the ownership stake in Vigil Neuroscience that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vigil Neuroscience's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vigil Neuroscience's value.| Shares | Rock Springs Capital Management Lp | 2024-06-30 | 472 K | Orbimed Advisors, Llc | 2024-06-30 | 448.9 K | Blackrock Inc | 2024-06-30 | 405 K | Goldman Sachs Group Inc | 2024-06-30 | 401.1 K | Ensign Peak Advisors Inc | 2024-06-30 | 395.1 K | Millennium Management Llc | 2024-06-30 | 334.8 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-06-30 | 289.5 K | Abrdn Plc | 2024-09-30 | 235 K | Woodline Partners Lp | 2024-06-30 | 206.6 K | Northpond Ventures, Llc | 2024-06-30 | 4.2 M | Artal Group S A | 2024-06-30 | 1.8 M |
Vigil Fundamentals
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 68.27 M | ||||
| Shares Outstanding | 39.65 M | ||||
| Shares Owned By Insiders | 21.27 % | ||||
| Shares Owned By Institutions | 80.15 % | ||||
| Number Of Shares Shorted | 513.3 K | ||||
| Price To Book | 1.66 X | ||||
| EBITDA | (88.47 M) | ||||
| Net Income | (82.64 M) | ||||
| Cash And Equivalents | 148.91 M | ||||
| Cash Per Share | 5.27 X | ||||
| Total Debt | 13.85 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 21.35 X | ||||
| Book Value Per Share | 3.24 X | ||||
| Cash Flow From Operations | (70.36 M) | ||||
| Short Ratio | 5.31 X | ||||
| Earnings Per Share | (2.11) X | ||||
| Target Price | 15.88 | ||||
| Number Of Employees | 64 | ||||
| Beta | 1.93 | ||||
| Market Capitalization | 141.54 M | ||||
| Total Asset | 140.86 M | ||||
| Retained Earnings | (222.77 M) | ||||
| Working Capital | 110.25 M | ||||
| Net Asset | 140.86 M |
About Vigil Neuroscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vigil Neuroscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vigil Neuroscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vigil Neuroscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Vigil Neuroscience Piotroski F Score and Vigil Neuroscience Valuation analysis. For more information on how to buy Vigil Stock please use our How to buy in Vigil Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vigil Neuroscience. If investors know Vigil will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vigil Neuroscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.11) | Return On Assets (0.40) | Return On Equity (0.70) |
The market value of Vigil Neuroscience is measured differently than its book value, which is the value of Vigil that is recorded on the company's balance sheet. Investors also form their own opinion of Vigil Neuroscience's value that differs from its market value or its book value, called intrinsic value, which is Vigil Neuroscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vigil Neuroscience's market value can be influenced by many factors that don't directly affect Vigil Neuroscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vigil Neuroscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vigil Neuroscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vigil Neuroscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.